RAFAEL
RUBIO GARCÍA
Profesor titular de universidad
Klinikum der Universität München
Múnich, AlemaniaPublications en collaboration avec des chercheurs de Klinikum der Universität München (2)
2020
-
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
Journal of acquired immune deficiency syndromes (1999), Vol. 85, Núm. 3, pp. 325-330